BioSpace News Archive

Fortrea today announced that it will release its third quarter 2023 financial results before the market opens on Monday, November 13, 2023.

Shionogi Inc. will present new real-world and clinical data at IDWeek 2023 reinforcing the potential of ensitrelvir, its investigational oral antiviral, to treat the symptoms of COVID-19.

NovaBay ® Pharmaceuticals, Inc. announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of chronic dry eye with Avenova ® -branded products.

MC2 Therapeutics today announced presentation of highly positive Phase 2a data from MC2-32 (previously RGRN-305), its recently acquired novel HSP90 inhibitor for the treatment of hidradenitis suppurativa (HS), in a late-breaking news session at EADV.

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023.

ZyVersa Therapeutics, Inc. announces publication of a paper in the peer-reviewed journal, Nature Reviews Nephrology, that summarizes data highlighting how lipid accumulation in the kidneys contributes to CKD development and disease progression.

Tonix Pharmaceuticals Holding Corp. announced today that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix Pharmaceuticals, will present at the World Vaccine Congress Europe on Wednesday, October 18, 2023, at 2:45 p.m. CEST in Barcelona, Spain.

Kyowa Kirin Co., Ltd. announced that post-hoc analysis data from the Phase 2b study of rocatinlimab, an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming European Academy of Dermatology and Venereology Congress 2023 in Berlin, Germany in October 11-14, 2023.

Gritstone bio, Inc. today announced the presentation of results from three ongoing Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company’s CORAL program) at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA.

Coeptis Therapeutics Holdings, Inc. today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells.